Description of United Therapeutics's Business Segments

United Therapeutics Corporation is a pioneering healthcare company specializing in the development and commercialization of innovative therapies for patients with rare diseases, particularly those with significant unmet medical needs. The companys diverse product portfolio and services are organized across various therapeutic segments, focusing primarily on pulmonary hypertension, pediatric oncology, and organ transplantation.

1. Pulmonary Hypertension

Pulmonary hypertension (PH) is a serious condition characterized by high blood pressure in the pulmonary arteries, leading to symptoms such as breathlessness, fatigue, and impaired exercise capacity. United Therapeutics is actively engaged in providing a multitude of therapies aimed at managing this debilitating disease:

- Tyvaso (treprostinil) Inhalation Solution: Designed for patients with pulmonary arterial hypertension (PAH), Tyvaso is administered via a nebulizer, allowing for direct delivery to the lungs. Patients can use this medication multiple times a day to enhance their breathing and increase their ability to engage in physical activity.

- Remodulin (treprostinil) Injection: This injectable formulation offers an alternative route of administration for PAH patients who may benefit from continuous infusion via a subcutaneous or intravenous pump. Remodulin is crucial for managing the symptoms of PAH and improving the quality of life.

- Orenitram (treprostinil) Extended-Release Tablets: Orenitram provides a more convenient oral delivery option for patients dealing with PAH. These extended-release tablets are designed for once-daily dosing and are effective in managing disease symptoms.

- Adcirca (tadalafil): This oral therapy acts as a phosphodiesterase-5 inhibitor, working to relax the blood vessels in the lungs, allowing for better blood flow and oxygenation. It is another option available for patients experiencing PAH.

Neuroblastoma

United Therapeutics is also committed to developing targeted therapies for childhood cancers, particularly neuroblastoma, which is a malignancy that primarily affects young children. Its leading therapeutic agent for this indication is:

- Unituxin (dinutuximab): This monoclonal antibody treatment is specifically designed for patients with high-risk neuroblastoma. It plays a critical role in the post-chemotherapy treatment process, enhancing the immune systems ability to target and destroy cancer cells. Unituxin is used in conjunction with other therapies to improve overall treatment outcomes for these vulnerable patients.

Organ Transplantation

The company recognizes the challenges faced by organ transplant recipients, who often require lifelong immunosuppression to prevent transplant rejection. United Therapeutics offers:

- Hizentra (Immune Globulin Intravenous ): While primarily used for patients with primary immunodeficiency disorders, Hizentras role in the transplantation community focuses on helping to maintain a balanced immune response post-transplant. Its administration is important for minimizing the risk of infections and other complications associated with the need for immunosuppression.

Support Services

In addition to its extensive product offerings, United Therapeutics provides a range of support services designed to enhance patient care and navigate the challenges associated with rare diseases:

- Therapy Management Programs: These programs are designed to support patients in managing their treatment regimens, improving adherence, and maximizing therapeutic outcomes.

- Reimbursement Assistance: Understanding the complexities of healthcare reimbursement, United Therapeutics offers assistance programs to help patients access the treatments they need without undue financial burden.

- Clinical Trial Recruitment Assistance: The company actively engages in research to discover new therapies. It assists patients in finding suitable clinical trials that may be beneficial, providing opportunities for access to cutting-edge treatments.

Through its commitment to innovation and patient support, United Therapeutics Corporation is at the forefront of developing solutions for complex and often life-threatening conditions, striving to improve the lives of those affected by rare diseases.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Composition of United Therapeutics Corporation Revenues by Segments


Tyvaso DPI	42.26 %	of total Revenue
Nebulized Tyvaso	16.28 %	of total Revenue
Remodulin	16.2 %	of total Revenue
Orenitram	17.35 %	of total Revenue
Unituxin	6.86 %	of total Revenue
Adcirca	0.37 %	of total Revenue
Other	0.68 %	of total Revenue
Total Tyvaso	58.54 %	of total Revenue
U S	95.23 %	of total Revenue
U S Total Tyvaso	56.67 %	of total Revenue
U S Tyvaso DPI	42.26 %	of total Revenue
U S Nebulized Tyvaso	14.41 %	of total Revenue
U S Remodulin	13.92 %	of total Revenue
U S Orenitram	17.35 %	of total Revenue
U S Unituxin	6.27 %	of total Revenue
U S Adcirca	0.37 %	of total Revenue
U S Other	0.64 %	of total Revenue
ROW	4.77 %	of total Revenue
ROW Total Tyvaso	1.87 %	of total Revenue
ROW Nebulized Tyvaso	1.87 %	of total Revenue
ROW Remodulin	2.28 %	of total Revenue
ROW Unituxin	0.59 %	of total Revenue
ROW Other	0.04 %	of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments	Revenues (in millions $)	% (of total Revenues)
Tyvaso DPI	330.30	42.26 %
Nebulized Tyvaso	127.20	16.28 %
Remodulin	126.60	16.2 %
Orenitram	135.60	17.35 %
Unituxin	53.60	6.86 %
Adcirca	2.90	0.37 %
Other	5.30	0.68 %
Total Tyvaso	457.50	58.54 %
U S	744.20	95.23 %
U S Total Tyvaso	442.90	56.67 %
U S Tyvaso DPI	330.30	42.26 %
U S Nebulized Tyvaso	112.60	14.41 %
U S Remodulin	108.80	13.92 %
U S Orenitram	135.60	17.35 %
U S Unituxin	49.00	6.27 %
U S Adcirca	2.90	0.37 %
U S Other	5.00	0.64 %
ROW	37.30	4.77 %
ROW Total Tyvaso	14.60	1.87 %
ROW Nebulized Tyvaso	14.60	1.87 %
ROW Remodulin	17.80	2.28 %
ROW Unituxin	4.60	0.59 %
ROW Other	0.30	0.04 %
Total	781.50	100 %

Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment	Y/Y Revenue %	Q/Q Revenue %
Tyvaso DPI	9.19 %	-
Nebulized Tyvaso	-22.34 %	-
Remodulin	-8.39 %	-
Orenitram	12.34 %	-
Unituxin	-7.9 %	-
Adcirca	-51.67 %	-
Other	6 %	-
Total Tyvaso	-1.89 %	-
U S	-0.72 %	-
U S Total Tyvaso	0.41 %	-
U S Tyvaso DPI	9.19 %	-
U S Nebulized Tyvaso	-18.76 %	-
U S Remodulin	-9.48 %	-
U S Orenitram	12.34 %	-
U S Unituxin	-13.88 %	-
U S Adcirca	-51.67 %	-
U S Other	6.38 %	-
ROW	-16.74 %	-
ROW Total Tyvaso	-42.06 %	-
ROW Nebulized Tyvaso	-42.06 %	-
ROW Remodulin	-1.11 %	-
ROW Unituxin	253.85 %	-
ROW Other	0 %	-
Total	-1.62 %	-

Q1 three months ended (Mar 31 2026)
Income by Business Segments	Income (in millions $)	% (Profit Margin)
Tyvaso DPI	247.10	74.81 %
Nebulized Tyvaso	118.60	93.24 %
Remodulin	110.50	87.28 %
Orenitram	128.20	94.54 %
Unituxin	48.60	90.67 %
Adcirca	1.90	65.52 %
Other	-6.80	-
Total	274.90	35.18 %

Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment	Y/Y Income %	Q/Q Income %
Tyvaso DPI	-2.87 %	-
Nebulized Tyvaso	-23.63 %	-
Remodulin	-11.17 %	-
Orenitram	14.06 %	-
Unituxin	-8.3 %	-
Adcirca	-44.12 %	-
Other	-	-
Total	-14.68 %	-

Annual Report on United Therapeutics Corporation Divisions, Sales by Country


Tyvaso DPI	40.61 %	of total Revenue
Nebulized Tyvaso	18.4 %	of total Revenue
Remodulin	16.55 %	of total Revenue
Orenitram	15.61 %	of total Revenue
Unituxin	7.13 %	of total Revenue
Adcirca	0.94 %	of total Revenue
Other	0.75 %	of total Revenue
Total Tyvaso	59.01 %	of total Revenue
United States	95.42 %	of total Revenue
United States Total Tyvaso	57.3 %	of total Revenue
United States Tyvaso DPI	40.59 %	of total Revenue
United States Nebulized Tyvaso	16.71 %	of total Revenue
United States Remodulin	14.1 %	of total Revenue
United States Orenitram	15.61 %	of total Revenue
United States Unituxin	6.75 %	of total Revenue
United States Adcirca	0.94 %	of total Revenue
United States Other	0.72 %	of total Revenue
Rest-of-World	4.58 %	of total Revenue
Rest-of-World Total Tyvaso	1.71 %	of total Revenue
Rest-of-World Tyvaso DPI	0.02 %	of total Revenue
Rest-of-World Nebulized Tyvaso	1.69 %	of total Revenue
Rest-of-World Remodulin	2.45 %	of total Revenue
Rest-of-World Unituxin	0.38 %	of total Revenue
Rest-of-World Other	0.04 %	of total Revenue

Twelve months ended 2025
UTHR s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
Tyvaso DPI	1,292.50	40.61 %
Nebulized Tyvaso	585.70	18.4 %
Remodulin	526.80	16.55 %
Orenitram	496.90	15.61 %
Unituxin	226.80	7.13 %
Adcirca	30.00	0.94 %
Other	24.00	0.75 %
Total Tyvaso	1,878.20	59.01 %
Total	3,182.70	100 %
United States	3,037.00	95.42 %
United States Total Tyvaso	1,823.70	57.3 %
United States Tyvaso DPI	1,291.80	40.59 %
United States Nebulized Tyvaso	531.90	16.71 %
United States Remodulin	448.90	14.1 %
United States Orenitram	496.90	15.61 %
United States Unituxin	214.70	6.75 %
United States Adcirca	30.00	0.94 %
United States Other	22.80	0.72 %
Rest-of-World	145.70	4.58 %
Rest-of-World Total Tyvaso	54.50	1.71 %
Rest-of-World Tyvaso DPI	0.70	0.02 %
Rest-of-World Nebulized Tyvaso	53.80	1.69 %
Rest-of-World Remodulin	77.90	2.45 %
Rest-of-World Unituxin	12.10	0.38 %
Rest-of-World Other	1.20	0.04 %

Twelve months ended 2025
UTHR s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
Tyvaso DPI	1,081.90	83.71 %
Nebulized Tyvaso	558.50	95.36 %
Remodulin	477.50	90.64 %
Orenitram	468.20	94.22 %
Unituxin	209.30	92.28 %
Adcirca	16.90	56.33 %
Other	-14.00	-
Total	1,334.70	41.94 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth
Tyvaso DPI	25.05 %	22.22 %
Nebulized Tyvaso	-0.19 %	1.05 %
Remodulin	-2.1 %	-2.69 %
Orenitram	14.41 %	15.35 %
Unituxin	-4.99 %	-6.69 %
Adcirca	26.05 %	23.36 %
Other	8.6 %	-
Total Tyvaso	15.91 %	-
Total	10.61 %	11.68 %
United States	10.85 %	-
United States Total Tyvaso	15.52 %	-
United States Tyvaso DPI	25.03 %	-
United States Nebulized Tyvaso	-2.49 %	-
United States Remodulin	-3.3 %	-
United States Orenitram	14.41 %	-
United States Unituxin	-2.23 %	-
United States Adcirca	26.05 %	-
United States Other	19.37 %	-
Rest-of-World	5.81 %	-
Rest-of-World Total Tyvaso	30.7 %	-
Rest-of-World Tyvaso DPI	75 %	-
Rest-of-World Nebulized Tyvaso	30.27 %	-
Rest-of-World Remodulin	5.41 %	-
Rest-of-World Unituxin	-36.65 %	-
Rest-of-World Other	-60 %	-

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.